Stock Traders Purchase High Volume of Call Options on Annexon (NASDAQ:ANNX)

Annexon, Inc. (NASDAQ:ANNX) was the target of unusually large options trading activity on Wednesday. Stock investors acquired 2,592 call options on the stock. This represents an increase of approximately 244% compared to the average daily volume of 754 call options.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ANNX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Monday, July 13th. Citigroup began coverage on shares of Annexon in a research report on Tuesday, July 21st. They issued a “market underperform” rating on the stock. The Goldman Sachs Group started coverage on shares of Annexon in a report on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a research report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Annexon in a report on Monday, July 20th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Annexon currently has a consensus rating of “Hold” and a consensus target price of $15.33.

Trending Headlines about Annexon

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: Annexon reported rapid improvements in strength and disability among the first 10 patients in the FORWARD study of tanruprubart for Guillain-Barré syndrome. The company expects to submit a U.S. Biologics License Application in the fourth quarter of 2026, providing a potentially important regulatory catalyst. Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
• Positive Sentiment: The company expanded the Phase 3 ARCHER II trial of vonaprument in geographic atrophy by adding a Month 24 dual primary endpoint alongside the Month 15 endpoint. This gives the study two independent efficacy time points while preserving the Month 15 data readout expected in the fourth quarter of 2026. An open-label extension study will assess longer-term safety and potential vision-preservation benefits. Annexon Expands Vonaprument Phase 3 Program
• Positive Sentiment: Annexon secured access to a credit facility of up to $200 million, with $50 million initially drawn. Combined with $209.2 million in cash, cash equivalents and short-term investments at June 30, management expects funding to support operations and milestones into 2028.
• Neutral Sentiment: Unusually high call-option activity and reported insider purchases suggest some bullish positioning, but these trading signals do not establish future clinical or commercial success.
• Negative Sentiment: Second-quarter adjusted results were weaker than expected: Annexon posted a loss of $0.28 per share versus the $0.24 consensus estimate. The net loss increased to $55.3 million from $49.2 million a year earlier, while research and development expenses rose to $46.6 million. The earnings shortfall appears to be the immediate reason shares came under pressure. Annexon shares fall as second-quarter loss exceeds Wall Street forecasts
• Negative Sentiment: Annexon remains an unprofitable, clinical-stage biotechnology company dependent on financing and successful trial results. The added Month 24 ARCHER II analysis extends the full data timeline into the third quarter of 2027, leaving investors exposed to development and regulatory risks beyond the nearer-term Month 15 readout.

Annexon Stock Down 0.2%

Annexon stock opened at $5.33 on Thursday. The company has a market capitalization of $873.27 million, a PE ratio of -4.37 and a beta of 1.18. Annexon has a 12-month low of $2.03 and a 12-month high of $7.18. The firm’s fifty day moving average is $5.35 and its 200 day moving average is $5.53.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). Sell-side analysts expect that Annexon will post -0.92 EPS for the current fiscal year.

Insider Activity

In related news, Director Muneer A. Satter purchased 613,497 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was acquired at an average cost of $5.41 per share, for a total transaction of $3,319,018.77. Following the completion of the purchase, the director owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. This represents a 6.31% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 10.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after acquiring an additional 2,785 shares in the last quarter. Landscape Capital Management L.L.C. bought a new stake in shares of Annexon during the fourth quarter valued at approximately $50,000. CIBC Bancorp USA Inc. acquired a new position in shares of Annexon during the third quarter worth approximately $31,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Annexon during the fourth quarter worth approximately $52,000. Finally, Abel Hall LLC bought a new position in shares of Annexon in the 1st quarter worth $61,000.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.